Prostate最新文献

{"title":"Mycobacterium Tuberculosis: The Hidden Bacteria in Chronic Prostatitis.","authors":"André Avarese Figueiredo, Augusto de Azevedo Barreto, Victor Silvestre Soares Fanni","doi":"10.1002/pros.70072","DOIUrl":"https://doi.org/10.1002/pros.70072","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zonal-Specific Risk Stratification Integrating Magnetic Resonance Imaging and Prostate-Specific Antigen Density for Optimizing Prostate Biopsy Selection in Prostate-Specific Antigen 4-20 ng/mL Patients.","authors":"Liqin Yang, Ximing Wang, Zhiping Li, Fawei Huang, Yongsheng Zhang, Feng Cui, Pengfei Jin","doi":"10.1002/pros.70075","DOIUrl":"https://doi.org/10.1002/pros.70075","url":null,"abstract":"<p><strong>Objective: </strong>To explore the stratification differences of MRI and prostate-specific antigen (PSA) density (PSAD) in the peripheral zone (PZ) and transition zone (TZ) lesions, in order to optimize the biopsy decision for patients with PSA 4-20 ng/mL.</p><p><strong>Methods: </strong>This retrospective study analyzed 1524 patients undergoing MRI and biopsy. Lesions were grouped by PZ and TZ and the differences of PSAD within the subgroups were explored. A zonal-specific risk matrix was constructed by integrating the Prostate Imaging Reporting and Data System (PI-RADS) categories and PSAD in overall, PZ, and TZ cohorts. Low or high-threshold pathway was constructed by 10% or 30% clinically significant prostate cancer (csPCa) probability for PZ and TZ. Six biopsy pathways were then formed and evaluated by the biopsy avoidance, csPCa detection, and positive predictive value (PPV). Finally, decision curve analysis (DCA) was employed to evaluate the net benefit associated with each pathway.</p><p><strong>Results: </strong>PZ lesions exhibited higher PSAD than TZ counterparts in equivalent PI-RADS categories (p < 0.05). In the risk matrix, for PI-RADS 1-2 lesions, TZ required PSAD ≥ 0.15 ng/mL/cm³ while PZ ≥ 0.20 ng/mL/cm³ to achieve > 10% csPCa risk. For PI-RADS 3 lesions, thresholds were ≥ 0.15 ng/mL/cm³ (TZ) and ≥ 0.20 ng/mL/cm³ (PZ) to trigger biopsy at > 30% csPCa risk. Among six pathways, the \"PZ high + TZ high\" pathway (PSAD ≥ 0.20 ng/mL/cm³ for PZ and ≥ 0.15 ng/mL/cm³ for TZ in PI-RADS 3) achieved optimal balance, detecting 86.6% of csPCa while avoiding 48.0% of unnecessary biopsies, with a PPV of 69.1% (F1-score = 0.77). DCA confirmed superior net clinical benefit for this pathway at ≥ 20% risk thresholds.</p><p><strong>Conclusion: </strong>In the risk stratification of MRI and PSAD, considering zonal specific of the lesion is helpful to improve biopsy decisions in patients with PSA 4-20 ng/mL.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zinc Ameliorates Inflammation and Sperm Parameters in Rats With Experimental Autoimmune Prostatitis.","authors":"Ziqi Chen, Jing Ma, Xiuqiao Yu, Xuan Liu, Shusong Wang, Zhenxian Wang","doi":"10.1002/pros.70067","DOIUrl":"https://doi.org/10.1002/pros.70067","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;It is quite common for patients diagnosed with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) to have abnormal sperm parameters. Studies have shown that zinc ameliorates male sperm parameters and ameliorates prostatitis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This study aims to investigate the effect of zinc on ameliorating ventral prostatitis in a rat model with experimental autoimmune prostatitis (EAP) by inhibiting the IKKβ/IκBα/NF-κB pathway mediated by inflammatory factors. It also aims to demonstrate that zinc treatment can attenuate a range of abnormal sperm parameters induced by experimental autoimmune prostatitis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Sixteen rats were used to obtain the prostate antigen, and three groups of eight were used as experimental groups. The control group (NC group), the model group (EAP group), and the model + zinc group (EAPZ group). Following the official start of the experiment, the EAP was induced by multipoint intradermal immunization using a mixture containing 30 mg/ml prostate antigen and complete freund's adjuvant (CFA) on days 0 and 28 in the EAP and EAPZ groups, respectively. In contrast, the rats in the NC group were immunized with an equal volume mixture of normal saline and CFA at the same site and at the same time. After the model matured on day 42, rats in the EAPZ group received zinc gavage treatment (10 mg/kg/day) for 4 weeks. Rats in both the NC and EAP groups were given the same amount of normal saline by gavage. All rats were killed at 22 weeks of age. Prostate, epididymis, and serum were extracted from rats for further experiments.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The study revealed that rats in the EAP group exhibited elevated levels of IL-1β, IL-6, and TNF-α in the ventral prostate lobe and higher expression levels of acid phosphatase (ACP) in serum. The total sperm count, viability, motility, and mitochondrial membrane potential (MMP) decreased significantly. Furthermore, serum zinc levels and ventral prostate zinc levels were reduced. Free zinc was also reduced in the ventral prostate and sperm of rats. The ventral prostate lobe tissues from EAP rats showed decreased protein expression of ZNT4, ZNT9, ZIP1, ZIP8, and ZIP14, while protein expression levels of IKKβ, IκBα, p-IκBα, p-NF-κB were increased. The overall data demonstrated damage to ventral prostate tissue, imbalance of zinc homeostasis, activation of inflammatory pathways, and impairment of sperm parameters in EAP rats. In the EAPZ group, there was a reduction in the expression levels of IL-1β, IL-6, and TNF-α. Conversely, sperm parameters and mitochondrial membrane potential exhibited an increase, while serum zinc and ventral prostate zinc levels demonstrated a rise. Additionally, the expression levels of the aforementioned zinc transporter and pathway proteins were restored.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The above phenomena indicating that zinc supplementation could restore the balance of ","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally Invasive Holmium Laser Enucleation of the Prostate (MiLEP) Vs. HoLEP: Retrospective Analysis of Perioperative Outcomes in a Propensity Score-Matched Cohort.","authors":"Jacob Schmidt, Bernhard Ralla, Andreas Maxeiner, Jorien Krediet, Holger Beutel, Ayoub Hidayat Allah, Nella Gagel, Henning Plage, Maha Ullmann, Robert Peters, Frank Friedersdorff, Martin Kanne","doi":"10.1002/pros.70016","DOIUrl":"10.1002/pros.70016","url":null,"abstract":"<p><strong>Background: </strong>Holmium laser enucleation of the prostate (HoLEP) is a well-established, size-independent surgical treatment offering favorable perioperative outcomes. Recently, minimal invasive laser enucleation of the prostate (MiLEP) has been introduced as a miniaturized approach utilizing a 22 Fr endoscope. However, comparative perioperative data on MiLEP versus HoLEP remain scarce.</p><p><strong>Materials and methods: </strong>A retrospective propensity-matched (PSM) cohort analysis was conducted, comparing the perioperative outcomes of the first 100 MiLEPs performed at our center versus standard HoLEP. After the PSM of 2187 patients, data from 200 patients (HoLEP: n = 100, MiLEP: n = 100) treated at a high-volume laser center were analyzed. Key parameters included operative time, enucleated tissue volume, complication rates, and catheterization duration. Statistical significance was set at p < 0.05.</p><p><strong>Results: </strong>Demographic characteristics, overall operative (36 vs. 35 min, p = 0.87), and enucleation times (22 vs. 23 min, p = 0.68) were comparable between MiLEP and HoLEP. However, MiLEP showed significantly shorter median morcellation times (5 vs. 3 min, p = 0.03), while coagulation time was longer (6 vs. 5 min, p = 0.02). Overall, complication rates were similar between both groups (15% vs. 16%, p = 0.85), with similar Clavien-Dindo distributions (Grade II: 13% vs. 11%; Grade IIIb: 2% in both groups). Recatheterization (8% vs. 4%, p = 0.23), macrohematuria requiring prolonged catheterization (1% vs. 5%, p = 0.1), and postoperative fever (4% vs. 5%, p = 0.73) showed no significant differences and were size-independent across prostates < 30, 30-59, and > 60 mL.</p><p><strong>Conclusion: </strong>Implementation of MiLEP is safe and feasible in a center with HoLEP experience, demonstrating comparable perioperative outcomes. The miniaturized approach maintains surgical efficiency across different prostate sizes while reducing instrument size. Further studies are necessary to evaluate long-term functional outcomes and confirm the potential benefits of MiLEP regarding urethral trauma.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1299-1306"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy.","authors":"Emily Chan, Stephanie L Pugh, Jeffry P Simko, Felix Feng, William U Shipley, Himanshu R Lukka, Jean-Paul Bahary, Thomas M Pisansky, Kenneth Lee Zeitzer, Elizabeth Gore, Jason A Efstathiou, Seth A Rosenthal, Alexander G Balogh, Richard D Lovett, Anthony Wong, Robert T Dess, L Scott McGinnis, Michael Kuettel, Luda DeMora, Howard M Sandler","doi":"10.1002/pros.70018","DOIUrl":"10.1002/pros.70018","url":null,"abstract":"<p><strong>Background: </strong>We aim to evaluate whether increased lymph node yield at prostatectomy (RP) is associated with improved outcomes in NRG/RTOG 9601, a randomized clinical trial of men who underwent either radiation (RT) alone or RT + bicalutamide for PSA elevation following RP for pT2/T3 prostate cancer.</p><p><strong>Methods: </strong>We reviewed available pathology reports for patients in NRG/RTOG 9601 to determine the nodal count at RP. Cox proportional hazards models were used to assess effect of lymph nodes yield, arm (RT alone or RT + bicalutamide), Gleason score, positive margins, and seminal vesicle invasion on the following endpoints: times to local and distant failure and overall and disease-specific survival.</p><p><strong>Results: </strong>Of 760 patients, 552 (73%, 276 in each arm) had complete data available. Median node count in the entire cohort was 6 (range: 0-33, IQR: 3-9). There were no significant differences between arms in terms of patient demographic or clinical characteristics, including total lymph nodes removed in either arm. There was no significant association between total lymph nodes and overall or disease-specific survival with both arms combined and when adjusting for arm. Notably, interaction analysis revealed that in seminal vesicle invasion, there was a significant association between lymph node yield and OS and DSS (HR = 0.91, 95% CI: 0.83-0.99, p = 0.034; HR = 0.87, 95% CI: 0.77-0.99, p = 0.029, respectively).</p><p><strong>Conclusions: </strong>Although lymph node yield in NRG/RTOG 9601 did not show association with adverse outcomes in the entire cohort or either arm alone, there was significant association between lymph node yield and adverse outcomes when seminal vesicle invasion was present. The therapeutic benefit of extensive lymph node dissection remains uncertain but could be more relevant in higher risk patients.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1315-1322"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered Glycosylation of PSA in Prostate Cancer Tissue.","authors":"Hannu Koistinen, Ruusu-Maaria Merivirta, Timo-Pekka Lehto, Anna Lempiäinen, Andrew Erickson, Ulf-Håkan Stenman, Antti Rannikko, Tuomas Mirtti","doi":"10.1002/pros.70014","DOIUrl":"10.1002/pros.70014","url":null,"abstract":"<p><strong>Background: </strong>The glycosylation of proteins is commonly altered in cancer. This offers novel opportunities for cancer biomarker development. As prostate-specific antigen (PSA) is a glycoprotein, identification of cancer-specific PSA-glycoforms is feasible. Such PSA-glycoforms may provide valuable diagnostic and prognostic information.</p><p><strong>Methods: </strong>PSA-glycoforms were studied in tissues, using in situ proximity-ligation assay (PLA)-based detection with a PSA-specific antibody and 25 different glycan-binding lectins.</p><p><strong>Results: </strong>Using 25 different lectins and a small tissue microarray (TMA), we showed that glycosylation of PSA in cancerous tissues is different from that in benign prostate. In a larger TMA with samples from 162 patients, PSA-glycoforms detected by succinylated wheat germ (WGA_succ) and Vicia villosa (VVA) lectins were enriched in cancerous tissues as compared to adjacent benign tissues from the same patients (p < 10^-4 for both, Kruskal-Wallis H test), although strong total PSA staining was more often found in benign tissues (p = 6*10^-14).</p><p><strong>Conclusions: </strong>We showed here that glycosylation of PSA is changed in situ in prostate cancer. The identified lectins, showing preferential binding to cancer-associated PSA-glycoforms, will aid the future development of a diagnostic serum test of prostate cancer. Such a test has potential to revolutionize prostate cancer diagnostics.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1290-1298"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor.","authors":"Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, Masanobu Saruta, Atsuhiko Yoshizawa, Kiyoshi Takahara, Takuya Tsujino, Ryoichi Maenosono, Yuki Yoshikawa, Wataru Fukuokaya, Takafumi Yanagisawa, Takahiro Kimura, Takeshi Hashimoto, Yosuke Hirasawa, Yoshio Ohno, Kazutoshi Fujita","doi":"10.1002/pros.70017","DOIUrl":"10.1002/pros.70017","url":null,"abstract":"<p><strong>Objectives: </strong>We evaluated the association between initial prostate-specific antigen (iPSA) levels and prognosis in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and extensive bone metastases treated with androgen receptor signaling inhibitors (ARSI).</p><p><strong>Subjects and methods: </strong>This retrospective study included 276 de novo high-risk mHSPC patients with extensive bone metastases (extent of disease [EOD] score ≥ 2) who received ARSI as first-line therapy. The data were collected from institutions participating in the ULTRA Japan Study group. Patient data were collected from institutions affiliated with the ULTRAJ group. Patients were stratified into quartiles based on iPSA levels, and a cutoff value of 200 ng/mL was used for subgroup analysis. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves and Cox proportional hazards regression models. A restricted cubic spline analysis was conducted to evaluate the nonlinear association between iPSA levels and OS.</p><p><strong>Results: </strong>Kaplan-Meier analysis demonstrated significant associations between iPSA quartiles and OS (p = 0.030), with the lowest survival observed in the lowest iPSA group (Q1: < 200 ng/mL). A spline-based analysis suggested an inverted J-shaped association between iPSA and OS, with the lowest hazard ratio observed at 1664 ng/mL. Patients with iPSA < 200 ng/mL exhibited significantly shorter OS than those with higher levels (p = 0.015), while no significant difference in PFS was observed (p = 0.869).</p><p><strong>Conclusions: </strong>Initial PSA levels were associated with prognosis in high-risk mHSPC with extensive bone metastases. Although patients with relatively low iPSA had significantly shorter OS, those exhibited no significant difference in PFS, suggesting that patients with low iPSA could benefit from ARSI as the 1st line treatment.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1307-1314"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 31st Annual Prostate Cancer Foundation Scientific Retreat Report.","authors":"Andrea K Miyahira, Howard R Soule","doi":"10.1002/pros.70015","DOIUrl":"10.1002/pros.70015","url":null,"abstract":"<p><strong>Background: </strong>The 31st Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 24-26, 2024.</p><p><strong>Methods: </strong>The Annual PCF Scientific Retreat is the foremost international conference focused on emerging and cutting-edge basic, translational, and clinical prostate cancer research, as well as research from related disciplines with strong potential to advance prostate cancer understanding and improve patient outcomes.</p><p><strong>Results: </strong>The 2024 PCF Retreat featured research from many disciplines, including: (i) tumor metabolism; (ii) genomics of prostate cancer racial disparities; (iii) reprogramming macrophages in the tumor immune microenvironment; (iv) high impact clinical trials for patients with prostate cancer; (v) artificial intelligence (AI) in driving innovation in cancer research and cancer care; (vi) lessons from 20 years of STAMPEDE; (vii) the PCF-Veterans Administration (VA) partnership's impact in bringing precision medicine to Veterans; (viii) germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer; (ix) next generation theranostics; (x) emerging immunotherapies; (xi) advanced molecular biology of lethal prostate cancer; (xii) posttranscriptional gene regulation in prostate cancer; (xiii) new biotechnologies in genomic medicine; (xiv) advances in \"in vivo\" cell therapy platforms and novel small molecule cancer therapies; and (xv) an announcement on the PCF Gender Equity Networking Initiative.</p><p><strong>Conclusions: </strong>This report highlights key presentations from the 2024 PCF Scientific Retreat, with the aim of enhancing understanding of ongoing and emerging research, driving future progress in prostate cancer science and patient care, and inspiring broader public support for cancer research.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1253-1271"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LIAS Promotes Cuproptosis in Prostate Cancer Cells by Suppressing Glycolysis via the p53 Signaling Pathway.","authors":"Zhe Tang, Peichao Guo, Yuanhua Liu","doi":"10.1002/pros.70049","DOIUrl":"https://doi.org/10.1002/pros.70049","url":null,"abstract":"<p><strong>Background: </strong>Cuproptosis holds significant potential for optimizing cancer therapeutic strategies. However, the molecular mechanism by which lipoic acid synthase (LIAS) regulates cuproptosis in prostate cancer (PC) remains unclear.</p><p><strong>Methods: </strong>The GEPIA online tool and PC cell lines were used to analyze the expression of LIAS in PC. Cuproptosis characteristics were assessed using Cu²⁺ detection kits, Western blot (LIAS/FDX1), and immunofluorescence (DLAT oligomerization). Cell viability and proliferation capacity were determined by CCK-8 and colony formation assays. qPCR was used to detect p53 pathway gene expression. Glycolytic activity was analyzed by measuring extracellular acidification rate (ECAR), glucose uptake, and ATP levels. The regulatory relationship was validated using glycolytic inhibitors within the cuproptosis model.</p><p><strong>Results: </strong>LIAS expression was significantly downregulated in both PC and cuproptosis models. Overexpression of LIAS enhanced cuproptosis effects and suppressed the viability and proliferative capacity of cancer cells. Further analysis revealed that LIAS suppressed glycolysis by activating the p53 pathway, manifested by decreased extracellular acidification rate (ECAR), reduced glucose uptake, and diminished ATP levels. Notably, inhibition of glycolysis promoted cuproptosis, thereby impeding tumor progression.</p><p><strong>Conclusion: </strong>LIAS promotes cuproptosis and inhibits cancer cell proliferation in PC by activating the p53 signaling pathway to suppress glycolytic activity. These findings indicate that LIAS represents a potential therapeutic target for intervening in PC, and regulation of the glycolysis-cuproptosis axis may serve as an effective strategy for improving PC progression.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Human Development Index Category on Prostate Cancer Characteristics in Asia.","authors":"Shinichi Sakamoto, Xue Zhao, Mizuki Onozawa, Masaki Shiota, Jae Young Joung, Kyo Chul Koo, Levent Türkeri, Bahadır Şahin, Jasmine Lim, Teng Aik Ong, Peter Ka-Fung Chiu, Chi-Fai Ng, Tong-Lin Wu, Vu Le Chuyen, Bannakij Lojanapiwat, Jason L Letran, Lukman Hakim, Edmund Chiong, Ghazi M Al-Edwan, Satoru Taguchi, Yoshiyuki Yamamoto, Taketo Kawai, Tohru Nakagawa, Haruki Kume","doi":"10.1002/pros.70050","DOIUrl":"https://doi.org/10.1002/pros.70050","url":null,"abstract":"<p><strong>Purpose: </strong>As the incidence of prostate cancer rises in Asian countries, notable disparities in life expectancy, economic status, and education levels are observed. This study aimed to use the Human Development Index (HDI), which reflects these factors, to explore differences in prostate cancer diagnosis, staging, and initial treatment across various Asian nations and areas, and uncover the impact of socioeconomic factors on patient outcomes.</p><p><strong>Methods: </strong>We analyzed patients diagnosed with prostate cancer between January 2016 and December 2018 who were enrolled in the Asian Prostate Cancer Study Group (A-CaP). Patients were grouped into three HDI categories (medium, high, very high). A statistical comparison was conducted to evaluate differences in diagnostic methods and initial treatments across 12 Asian countries and areas based on HDI classification.</p><p><strong>Results: </strong>In total, 35,776 prostate cancer patients were included. Patients in the very high HDI group had lower PSA levels, fewer ISUP Grade 5 cases, and reduced metastatic disease (M1) compared to the other groups. Advanced diagnostic modalities (e.g., CT, MRI, and bone scintigraphy) were more commonly used in the very high HDI group. Imaging modalities were less frequently used in medium HDI countries with low PSA, and in high HDI countries with high PSA. Regarding treatment, patients in very high HDI countries and areas were more likely to receive radiation therapy or active surveillance. Surgical treatment was more common for metastatic patients in high and medium HDI countries and areas.</p><p><strong>Conclusion: </strong>This study highlights significant differences in prostate cancer management across 12 Asian countries and areas, emphasizing the influence of HDI on diagnostic and treatment outcomes.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}